Meta-Analysis and Review of In Silico Methods in Drug Discovery – Part 2: Principles of Cellular Complexity, Molecular Similarity and Singularity

Scope: This meta-analysis and review examine the conceptual and translational evolution of in silico methods in drug discovery, with emphasis on how chemical space, molecular similarity, cellular complexity, and localized singularities shape next-generation computational pharmacology. Building on Part 1, which defined the historical “what” and “when” of computational drug discovery, this Part 2 addresses the “how” and “why” by analyzing the principles that connect molecular descriptors, virtual screening, scaffold hopping, activity cliffs, and AI-driven lead prioritization. Methods: A systematic meta-analysis of 97 highly cited studies, selected from an initial pool of 300 top-cited publications, evaluates the ongoing paradigm shift from traditional computer-assisted drug discovery (CADD) toward advanced AI-driven workflows. Results: Thus, the current drug discovery practice enables the screening of ultra-large chemical libraries, mapping chemical diversity, generating hit maps, and prioritizing compounds through early ADMET assessment. The review shows that these methods can substantially accelerate early discovery and reduce experimental burden, but their impact remains mainly translational rather than automatically clinical. Limitations and Uncertainties: Major bottlenecks persist because model performance is constrained by chemical data quality, biological label uncertainty, missing or biased negative evidence, limited applicability-domain coverage, static representations of protein targets, incomplete treatment of solvent thermodynamics, and fragmented ADMET prediction. Conclusion: This work therefore argues that reliable AI-driven drug discovery requires more than faster prediction: it depends on fit-for-purpose datasets, explicit uncertainty handling, dynamic protein and solvent modeling, Systems ADMET, AI-PBPK integration, and closed-loop experimental validation. Overall, chemical space is presented not only as a repository of possible molecules, but as an operational framework for connecting molecular design, biological complexity, and clinically meaningful translation.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-11
DOI
https://doi.org/10.20944/preprints202611.1119.v1
Primary Topic
Computational Drug Discovery Methods
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Meta-Analysis and Review of In Silico Methods in Drug Discovery – Part 2: Principles of Cellular Complexity, Molecular Similarity and Singularity

Debosree Ghosh, John Victor Christy, Eugene N. Muratov, Domenico Fuoco et al.
Preprints.org
Computational Drug Discovery Methods
preprint

Meta-Analysis and Review of In Silico Methods in Drug Discovery – Part 2: Principles of Cellular Complexity, Molecular Similarity and Singularity

Debosree Ghosh, John Victor Christy, Eugene N. Muratov, Domenico Fuoco, Arife Uzundurukan, Mohamed Ibrahim Elzagheid, Holli‐Joi Martin, Sonia Morya, Christopher Teske, Shahidul Islam, Mark Nelson
preprint en

Abstract

Scope: This meta-analysis and review examine the conceptual and translational evolution of in silico methods in drug discovery, with emphasis on how chemical space, molecular similarity, cellular complexity, and localized singularities shape next-generation computational pharmacology. Building on Part 1, which defined the historical “what” and “when” of computational drug discovery, this Part 2 addresses the “how” and “why” by analyzing the principles that connect molecular descriptors, virtual screening, scaffold hopping, activity cliffs, and AI-driven lead prioritization. Methods: A systematic meta-analysis of 97 highly cited studies, selected from an initial pool of 300 top-cited publications, evaluates the ongoing paradigm shift from traditional computer-assisted drug discovery (CADD) toward advanced AI-driven workflows. Results: Thus, the current drug discovery practice enables the screening of ultra-large chemical libraries, mapping chemical diversity, generating hit maps, and prioritizing compounds through early ADMET assessment. The review shows that these methods can substantially accelerate early discovery and reduce experimental burden, but their impact remains mainly translational rather than automatically clinical. Limitations and Uncertainties: Major bottlenecks persist because model performance is constrained by chemical data quality, biological label uncertainty, missing or biased negative evidence, limited applicability-domain coverage, static representations of protein targets, incomplete treatment of solvent thermodynamics, and fragmented ADMET prediction. Conclusion: This work therefore argues that reliable AI-driven drug discovery requires more than faster prediction: it depends on fit-for-purpose datasets, explicit uncertainty handling, dynamic protein and solvent modeling, Systems ADMET, AI-PBPK integration, and closed-loop experimental validation. Overall, chemical space is presented not only as a repository of possible molecules, but as an operational framework for connecting molecular design, biological complexity, and clinically meaningful translation.

Preprints.org
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon